• Assessment of effectiveness of Gaviscon® Forte in the treatment of heartburn during pregnancy 

Assessment of effectiveness of Gaviscon® Forte in the treatment of heartburn during pregnancy 

HEALTH OF WOMAN.2016.7(113):84–90; doi 10.15574/HW.2016.113.84 
 

Assessment of effectiveness of Gaviscon® Forte in the treatment of heartburn during pregnancy 
 

Scherbinina M. B., Lugovskaya T. V., Ivanchenko N. A., Kovalenko G. A.

Dnipropetrovsk national University Oles Honchar

The family Planning center Tamara Lugovskoy, Dnipro

PI «Sixth Dnipropetrovsk city clinical hospital» of Dnipropetrovsk regional Council


Heartburn refers to the common dyspeptic manifestations experienced by up to 80% of pregnant women.


The objective: To evaluate the efficacy of Gaviscon® Forte in the treatment of heartburn during pregnancy based on clinical data, the opinion study of pregnant women receiving the drug, and physicians provides their curation, as well as exploring the views of gynecologists, which have the practice of conducting such patients.


Patients and methods. There were 94 pregnant women (Ј38 weeks of gestation), aged 18 to 34 years, with clinical manifestation of heartburn in the study. Oral Gaviscon® Forte mint suspension (the company «Rekkitt Benckiser Ukraine», UK) was appointed from 10 days to 1 month by 5–10 ml (1–2 tsp) 3 times a day after meals and 4th just before going to bed; or for 1 month by 5–10 ml (1–2 tsp) on demand. For the criteria of effectiveness of the drug have been taken: the time the relief of heartburn after a single reception; clinical dynamics of heartburn and related symptoms; opinion of pregnant women receiving the drug, and physicians provides their curation, opinions of gynecologists (n=258), which have the practice of conducting such patients. The evaluation of safety and tolerability of treatment was carried out by clinical monitoring.


Results. The majority of women (54.2%) had the first pregnancy. The appearance of heartburn on trimesters was: I – 11.7%; II – 25.5%; III – 62.8%. Before pregnancy, 63.8% of women had a disease of the digestive system. Heartburn severity was in majority cases between 4 (43.6%) and 3-points (26.6%) by 5-point scale. The duration of heartburn without the use of drugs was an average of 30 minutes. 54.3% of women experienced heartburn at least 1 time per week, and the rest – on a daily basis; 34.4% mentioned nocturnal episodes of heartburn. There were non-cardiac chest pain, 8.5%, dysphagia – 12.8%, the feeling of a lump in the throat – 23.4%, cough – 9.6%, mainly burping air – 60.6%, and hiccups – 43% in conjunction with heartburn. During treatment with Gaviscon® Forte frequency and intensity of heartburn and related symptoms gradually decreased. According to pregnant women after a single dose of the drug the relief of heartburn started in 5±2.6 min; control of GERD symptoms was observed after 11±3.8 days of regular therapy; the effectiveness of the drug was assessed as «good» and «very good» in 85.1% of cases. According to the doctors, they estimated the effectiveness of the drug as «good» and «very good» – in 86.2%. Of surveyed gynecologists, 39.5% used alginates in the treatment of heartburn during pregnancy. They assessed the effectiveness of Gaviscon® Forte as «good» and «very good» in 100% of cases.


Conclusions. The findings confirmed the high efficiency Gaviscon® Forte in the treatment of heartburn during pregnancy. The study allows confirming the advisability of administration of the drug for a quick and adequate removal of negative symptoms.


Key words: heartburn during pregnancy, alginates, Gaviscon® Forte.


REFERENCES

1. Rodriguez A, Bohlini G, Lindmark G. 2001. Symptoms across pregnancy in relation to psychosocial and biomedical factors. Acta Obstet. Gynecol. Scand. 80:213–223. http://dx.doi.org/10.1034/j.1600-0412.2001.080003213.x; PMid:11207486

2. Malfertheiner S, Malfertheiner M, Kropf S et al. 2012. A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol. 12:131. http://dx.doi.org/10.1186/1471-230X-12-131.

3. Malfertheiner SF, Malfer-theiner MV, Monkemuller K et al. 2009. Gastroesophageal reflux disease and management in advanced pregnancy: a prospective survey. Digestion. 2;79:115–120.

4. Vakil N, van Zanden SV, Kahrilas P et al. 2006. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am. J. Gastroenterol. 101:1900–1920. http://dx.doi.org/10.1111/j.1572-0241.2006.00630.x; PMid:16928254

5. Scherbinina MB, Lugovskaya TV, Ivanchenko NA. 2016. Izzhoga beremennyih: prichinyi i vozmozhnosti uluchsheniya kachestva zhizni zhenschin v etot period. Zdorove zhenschiny 2(108):18–23.

6. Argunova IA. 2015. Izzhoga beremennyih: zhiteyskaya meloch, kotoruyu nado terpet, ili gastroezofagealnaya reflyuksnaya bolezn, kotoruyu sleduet kupirovat? Poliklinika. Spetsvyipusk 3, Gastroenterologiya:14–18.

7. Instruktsiia dlia medychnoho zastosuvannia preparatu Haviskon® Forte m’iatna suspenziia, zatverdzheno Nakazom MOZ Ukrainy № 5 vid 04.01.2013, R.P. UA/6865/01/01.

8. Instruktsiia dlia medychnoho zastosuvannia preparatu Haviskon® m’iatni tabletky, zatverdzheno Nakazom MOZ Ukrainy № 109 vid 08.02.2014, R.P. UA/6865/02/01.

9. Strugala V, Dettmar PW, Sarratt K et al. 2010, Mar-Apr. A Randomized, controlled, crossover trial to investigatetimes to onset of the perception of soothing and cooling by over the counter heartburn treatments. J. Int. Med. Res. 38(2):449–457. http://dx.doi.org/10.1177/147323001003800208; PMid:20515559

10. De Bellis I, Epifani S, Maiorino R, Tardio R. 1999. Gastroesophageal reflux in pregnancy. GiornaleItaliano di Ostetricia e Ginecologia 1;21:17–19.

11. Uzan M, Uzan S, Sureau C, Richard-Berthe C. 1988. Pyrosis and regurgitations during pregnancy. Efficacy and innocuousness of a treatment with Gaviscon suspension. Revue Francaise de Gynecologie et d’Obstetrique 7–9;83:569–572.

12. Hutt HJ, Tauber O, Flach D. 1990. Gaviscon in the treatment of reflux disease. Results of an observational study. Fortschritte der Medizin. 108:598–600. PMid:2258131

13. Lindow SW, Regnґ ell P, Sykes J, Little S. 2003. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (gaviscon advance) in the treatment of heartburn during pregnancy. International Journal of Clinical Practice 3;57:175–179.

14. Strugala V, Bassin J, Swales VS et al. 2012. Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet. and Gynecol. 2012:481870. http://dx.doi.org/10.5402/2012/481870. Epub 2012, Nov 4.

15. Burkov SG. 2004. Izzhoga beremennyih. Ginekologiya. Prilozhenie k zhurnalu Consiliummedicum. 6:2. Elektronnyiy resurs: URL: http://old.consilium-medicum. com/ media/ gynecology/04_02/76.shtml

16. Ramu B, Mohan P, Raja-sekaran MS, Jayanthi V. 2011. Prevalence and risk factors for gastroesophageal reflux in pregnancy. Indian Journal of Gastroenterology 30(3):144–147. http://dx.doi.org/10.1007/s12664-010-0067-3; PMid:21125366

17. Moayyedi P, Axon AT. 2005. Gastroesophageal reflux disease: the extent of the problem. Aliment. Pharmacol. Ther. 22 (1):11–19. http://dx.doi.org/10.1111/j.1365-2036.2005.02605.x; PMid:16042655

18. Naumann CR, Zeling C, Napolitano PG, Ko CW. 2012. Nausea, vomiting, and heartburn in pregnancy: a prospective look at risk, treatment, and outcome. The Journal of Maternal-Fetal and Neonatal Medicine 25(8):1488–1493. http://dx.doi.org/10.3109/14767058.2011.644363; PMid:22122296

19. Berthon G. 2002. Aluminium speciation in relation to aluminium bioavailability, metabolism and toxiety. CoordGhem Rev. 228:319–341. http://dx.doi.org/10.1016/S0010-8545(02)00021-8